MAP7D3 and neoplasm: Collectively, our clinical findings provide first evidence to demonstrate the clinical relevance of MAP7D3 in TNBC that high expression of MAP7D3 is associated with tumor progression, LN metastasis, and poor survival outcomes of TNBC patients.